Ultragenyx Pharmaceutical will host a conference call on November 4, 2025, to discuss Q3 financial results and updates.
Quiver AI Summary
Ultragenyx Pharmaceutical Inc. announced that it will hold a conference call on November 4, 2025, at 5:00 p.m. ET to discuss its financial results and corporate updates for the quarter ending September 30, 2025. The conference call will be available via a live and recorded webcast on the company’s website. Ultragenyx focuses on developing treatments for serious rare and ultra-rare genetic diseases and has a portfolio that includes approved therapies and candidates aimed at high unmet medical needs. The company emphasizes efficient drug development to deliver effective therapies swiftly to patients.
Potential Positives
- Ultragenyx Pharmaceutical is hosting a conference call to discuss its financial results and corporate updates, indicating transparency and communication with stakeholders.
- The call allows for real-time engagement with investors and the opportunity to discuss the company’s efforts in developing therapies for rare diseases, reinforcing its commitment to addressing unmet medical needs.
- The company has a diverse portfolio of approved therapies and product candidates, highlighting its active role in addressing serious rare and ultra-rare genetic diseases.
Potential Negatives
- None
FAQ
When is Ultragenyx's conference call scheduled?
Ultragenyx's conference call is scheduled for 5:00 p.m. ET on Tuesday, November 4, 2025.
How can I access the Ultragenyx conference call?
You can access the conference call via a live and replayed webcast on Ultragenyx's website at https://ir.ultragenyx.com/events-presentations.
What will be discussed during the conference call?
The conference call will cover Ultragenyx's financial results and corporate update for the quarter ending September 30, 2025.
How long will the replay of the conference call be available?
The replay of the conference call will be available for three months after the event.
What is Ultragenyx Pharmaceutical Inc. known for?
Ultragenyx Pharmaceutical Inc. focuses on developing and commercializing novel treatments for serious rare and ultra-rare genetic diseases.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$RARE Congressional Stock Trading
Members of Congress have traded $RARE stock 2 times in the past 6 months. Of those trades, 2 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $RARE stock by members of Congress over the last 6 months:
- REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 2 purchases worth up to $30,000 on 08/08, 07/15 and 0 sales.
To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard.
$RARE Insider Trading Activity
$RARE insiders have traded $RARE stock on the open market 6 times in the past 6 months. Of those trades, 0 have been purchases and 6 have been sales.
Here’s a breakdown of recent trading of $RARE stock by insiders over the last 6 months:
- HOWARD HORN (Chief Financial Officer) sold 7,942 shares for an estimated $250,252
- CORAZON (CORSEE) D. SANDERS sold 2,405 shares for an estimated $89,922
- KARAH HERDMAN PARSCHAUER (EVP and Chief Legal Officer) sold 2,450 shares for an estimated $76,366
- ERIC CROMBEZ (EVP and Chief Medical Officer) sold 520 shares for an estimated $20,404
- THEODORE ALAN HUIZENGA (SVP, Chief Accounting Officer) has made 0 purchases and 2 sales selling 148 shares for an estimated $4,503.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$RARE Hedge Fund Activity
We have seen 163 institutional investors add shares of $RARE stock to their portfolio, and 157 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- JPMORGAN CHASE & CO added 2,951,397 shares (+953.7%) to their portfolio in Q2 2025, for an estimated $107,312,794
- FMR LLC added 2,223,166 shares (+582.9%) to their portfolio in Q2 2025, for an estimated $80,834,315
- BAKER BROS. ADVISORS LP added 1,196,578 shares (+75.9%) to their portfolio in Q2 2025, for an estimated $43,507,576
- ASSENAGON ASSET MANAGEMENT S.A. removed 911,086 shares (-78.3%) from their portfolio in Q3 2025, for an estimated $27,405,466
- FARALLON CAPITAL MANAGEMENT LLC added 898,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $32,651,280
- ADAGE CAPITAL PARTNERS GP, L.L.C. removed 619,526 shares (-28.8%) from their portfolio in Q2 2025, for an estimated $22,525,965
- WELLINGTON MANAGEMENT GROUP LLP removed 577,678 shares (-23.6%) from their portfolio in Q2 2025, for an estimated $21,004,372
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$RARE Analyst Ratings
Wall Street analysts have issued reports on $RARE in the last several months. We have seen 6 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 09/09/2025
- Cantor Fitzgerald issued a "Overweight" rating on 09/05/2025
- Canaccord Genuity issued a "Buy" rating on 08/08/2025
- Morgan Stanley issued a "Overweight" rating on 07/14/2025
- Guggenheim issued a "Buy" rating on 06/20/2025
- William Blair issued a "Outperform" rating on 05/28/2025
To track analyst ratings and price targets for $RARE, check out Quiver Quantitative's $RARE forecast page.
$RARE Price Targets
Multiple analysts have issued price targets for $RARE recently. We have seen 8 analysts offer price targets for $RARE in the last 6 months, with a median target of $65.0.
Here are some recent targets:
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $80.0 on 09/09/2025
- Kristen Kluska from Cantor Fitzgerald set a target price of $105.0 on 09/05/2025
- Whitney Ijem from Canaccord Genuity set a target price of $128.0 on 08/08/2025
- Laura Chico from Wedbush set a target price of $34.0 on 07/14/2025
- Jeffrey Hung from Morgan Stanley set a target price of $55.0 on 07/14/2025
- Tiago Fauth from Wells Fargo set a target price of $65.0 on 07/10/2025
- Debjit Chattopadhyay from Guggenheim set a target price of $64.0 on 06/20/2025
Full Release
NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for the quarter ending September 30, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com .
Contact Ultragenyx
Investors
Joshua Higa
[email protected]
Media
Jess Rowlands
[email protected]
